Data Featured at DDW 2026

Johnson&Johnson

Digestive Disease Week

Chicago, Illinois
May 2-5, 2026

J&J Sponsored Studies

Abstract number	Title	Presentation time (CST)
JNJ-4804 studies		
DUET-CD study		
	Late-Breaking Oral Presentation	
979f	Efficacy and safety of the first co-antibody therapy, JNJ-78934804, in patients with moderately to severely active Crohn's disease refractory to systemic therapies	Tuesday, May 5 9:15 – 9:30 a.m.
DUET-UC study		
	Late-Breaking Oral Presentation	
1058d	Efficacy and safety of the first co-antibody therapy, JNJ-78934804, in patients with moderately to severely active ulcerative colitis refractory to systemic therapies	Tuesday, May 5 11:15 – 11:30 a.m.
Guselkumab studies		
FUZION study		
	Late-Breaking Oral Presentation	
1058b	Guselkumab for perianal fistulizing Crohn's disease: Week 24 results from the Phase 3, randomized, double-blind, placebo-controlled, multicenter FUZION study	Tuesday, May 5 10:45 –11:00 a.m.
QUASAR data		
	Poster Presentations	
Su1645*	Efficacy and safety of guselkumab for ulcerative colitis through week 140 of the QUASAR long-term extension study	Sunday, May 3 12:30 – 1:30 p.m.
Su1666*	Association of endoscopic, histologic, and composite outcomes with long-term guselkumab efficacy in ulcerative colitis: 2-year results from the QUASAR long-term extension	Sunday, May 3 12:30 – 1:30 p.m.
Mo1518*	Symptomatic improvement with intravenous guselkumab induction therapy is observed early in patients with moderately to severely active ulcerative colitis: post-hoc analysis of QUASAR	Monday, May 4 12:30 – 1:30 p.m.
Mo1516	Mayo Endoscopic Subscore changes in participants with moderately to severely active ulcerative colitis treated with guselkumab in the QUASAR long-term extension	Monday, May 4 12:30 – 1:30 p.m.
ASTRO data		
	Poster Presentations	
Mo1519*	Efficacy of subcutaneous guselkumab in moderately to severely active ulcerative colitis by induction week 12 clinical response status: week 48 results from the Phase 3 ASTRO study	Monday, May 4 12:30 – 1:30 p.m.
Mo1531*	Evaluation of complete bowel symptomatic remission in patients with moderately to severely active ulcerative colitis	Monday, May 4 12:30 – 1:30 p.m.
QUASAR/ASTRO study		
	Poster Presentation	
Mo1532*	Intravenous and subcutaneous guselkumab induction are similarly efficacious in patients with ulcerative colitis across weight quartile and bmi subgroups: week 12 results from the Phase 3 QUASAR and ASTRO studies	Monday, May 4 12:30 – 1:30 p.m.

*Encore abstract

GALAXI data		
Oral Presentations		
OP726*	Efficacy and safety of guselkumab in participants with moderately to severely active Crohn's disease who had maintenance dose adjustment: results from the Phase 3 GALAXI 2 & 3 long-term extension	Monday, May 4 10:30 – 10:45 a.m.
OP981*	Extraintestinal manifestations in participants with moderately to severely active Crohn's disease: Results from the Phase 3 GALAXI 2 & 3 studies	Tuesday, May 5 8:15 – 8:30 a.m.

GALAXI/GRAVITI data		
Poster Presentations		
Mo1534*	Efficacy of intravenous and subcutaneous guselkumab induction by weight and body mass index in patients with Crohn's disease: Results from the Phase 3 GALAXI and GRAVITI studies	Monday, May 4 12:30 – 1:30 p.m.
Tu1500*	Unsupervised machine learning to identify distinct CDAI-based response patterns to guselkumab in participants with Crohn's disease: Post hoc analysis of the pooled GRAVITI and GALAXI 2/3 studies	Tuesday, May 5 12:30 – 1:30 p.m.

Other guselkumab data		
Oral Presentations		
OP95*	Pregnancy outcomes in maternal exposure to guselkumab: Review of cases reported to the Company Global Safety Database	Saturday, May 2 10:15 – 10:30 a.m.
OP98*	Safety of guselkumab in patients aged ≥60 years with immune-mediated inflammatory diseases: a pooled analysis of registrational trials in UC, CD, PsA and PsO	Saturday, May 2 11:00 – 11:15 a.m.

Icotrokinra study		
ANTHEM data		
Oral Presentations		
OP27*	Icotrokinra, the first targeted oral peptide that selectively blocks the interleukin-23 receptor, reduces systemic and tissue inflammatory burden in ulcerative colitis: results from the ANTHEM-UC study	Saturday, May 2 8:30 – 8:45 a.m.
OP487	Efficacy of icotrokinra, the first targeted oral peptide that selectively blocks the interleukin-23 receptor, in ulcerative colitis patients with or without prior intolerance or inadequate response to advanced therapies: results from the ANTHEM-UC study	Sunday, May 3 3:15 – 3:30 p.m.

Ustekinumab studies		
UNIFI Jr data		
Oral Presentation		
OP725*	Safety and efficacy of ustekinumab in pediatric ulcerative colitis (UC): results from the Phase 3 UNIFI Jr study	Monday, May 4 10:15 – 10:30 a.m.
Poster Presentation		
Mo1629*	Exposure optimization substudy (EOS) of ustekinumab in pediatric ulcerative colitis (UC): q4w results from the Phase 3 UNIFI Jr study	Monday, May 4 12:30 – 1:30 p.m.

UNITI Jr data		
Poster Presentations		
Su1507*	Endoscopic and histologic results from the UNITI Jr study of ustekinumab in pediatric Crohn's disease	Sunday, May 3 12:30 – 1:30 p.m.
Tu1439	Ustekinumab pharmacokinetics and exposure-response relationships in pediatric patients with moderately to severely active Crohn's disease: results from UNITI Jr Phase 3 study	Tuesday, May 5 12:30 – 1:30 p.m.

Johnson&Johnson

*Encore abstract

Oral Presentations		
OP406*	Dose escalation in participants with primary/secondary loss of response to conventional dosing of ustekinumab in paediatric Crohn's disease (UNITI Jr Study)	Sunday, May 3 10:30 – 10:45 a.m.
OP404*	The UNITI Jr Study: Safety and efficacy results of ustekinumab in paediatric patients with Crohn's disease	Sunday, May 3 10:00 – 10:15 a.m.

AI studies		
ARGES-Ulcer CD data		
Oral Presentation		
OP88	ARGES-Ulcer: A Continuous, AI-derived ulcer burden score correlating with clinical and treatment response measures in Crohn's disease (CD)	Saturday, May 2 10:00 – 10:15 a.m.
Poster Presentation		
Tu1498	ARGES-Ulcer: A high-performance, generalizable AI model for Ulcer segmentation in Crohn's disease from endoscopy videos	Tuesday, May 5 12:30 – 1:30 p.m.

ARGES-UC data		
AGA Presidential Plenary		
Sp837	ARGES-UC: AI-based continuous scoring for disease severity in ulcerative colitis to increase sensitivity of treatment differentiation and trial design optimization	Monday, May 4 11:02 – 11:09 a.m.
Oral Presentation		
OP169	ARGES-UC: AI-based continuous scoring for disease severity in ulcerative colitis to increase sensitivity of treatment differentiation and trial design optimization	Saturday, May 2 2:00 – 2:15 p.m.

ARGES-Ulcer study		
Poster Presentation		
Tu1515	ARGES-Ulcer score: A continuous AI-derived SES-CD subcomponent for Crohn's disease severity assessment and clinical endpoint recapitulation	Tuesday, May 5 12:30 – 1:30 p.m.

Market Access and Real-World Evidence

Abstract number	Title	Presentation time (CST)
Poster Presentations		
Sa1521	Impact of endoscopic remission on long-term outcomes and IBD-related surgery in patients with ulcerative colitis: a retrospective cohort analysis from the Crohn's & Colitis foundation database	Saturday, May 2 12:30 – 1:30 p.m.
Sa1520	Long-term clinical outcomes, IBD-related surgery, and steroid use in patients with Crohn's disease in endoscopic remission: a retrospective cohort analysis from the Crohn's & Colitis foundation database	Saturday, May 2 12:30 – 1:30 p.m.
Sa1531	Wearable-derived physiologic signals differentiate inflammation from remission after biologic initiation in inflammatory bowel disease	Saturday, May 2 12:30 – 1:30 p.m.
Sa1530	Wearable-derived sleep metrics differentiate responders from non-responders following biologic therapy in inflammatory bowel disease	Saturday, May 2 12:30 – 1:30 p.m.

Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. There is no guarantee that the pipeline products or investigational uses will receive FDA approval. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.

Johnson&Johnson

*Encore abstract